All News #Library
Others
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte
20 Sep 2024 //
PR NEWSWIRE
Biosyngen Presents SUPER-T Technology At ESMO 2024
19 Sep 2024 //
PR NEWSWIRE
Biosyngen`s BRG01 Enters Phase II For EBV-Specific CAR-T Therapy
16 Jul 2024 //
PR NEWSWIRE
Biosyngen Announces FDA Fast Track Designation for BST02
01 Feb 2024 //
PR NEWSWIRE
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03
11 Sep 2023 //
PR NEWSWIRE

Market Place
Sourcing Support